Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that its independent Data and Safety Monitoring Board (DSMB) has completed a scheduled interim review of its ongoing FDA-approved multinational Phase I/IIa clinical trial for CMND-100, a proprietary, non-hallucinogenic neuroplastogen, in the treatment of alcohol use disorder (AUD). The company also announced that another site has been added to the trial with the commencement of patient enrollment at the Tel Aviv Sourasky Medical Center (TASMC).
In a statement, Dr. Adi Zuloff-Shani, PhD, CEO of Clearmind, commented, “This DSMB recommendation is a pivotal milestone for Clearmind and reinforces our confidence in CMND-100’s safety and therapeutic potential. We believe that the positive interim data from our first cohort, combined with the DSMB ‘s endorsement to proceed, positions us to accelerate enrollment and advance this innovative treatment toward addressing the unmet needs in alcohol use disorder. We appreciate the significant contributions of our clinical sites and study participants, whose involvement has been instrumental in advancing this program toward its next milestones.”
Regarding the addition of the TASMC site to Clearmind’s Phase I/IIa AUD trial, Dr. Adi Zuloff-Shani remarked, “The recruitment of the first patient at TASMC is a significant step that further accelerates our global trial. We are grateful to Prof. (David) Zeltser and the entire TASMC team for their commitment and exited to advance CMND-100 toward potentially transforming the treatment landscape for AUD.”
